m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01516)
Name
Menadione
Synonyms
Menadion; Menadionum; Menaphthon; Menaphthone; Menaphtone; Menaquinone 0; Mitenon; Mitenone; Panosine; Prokayvit; Synkay; Aquakay; Aquinone; Hemodal; Juva-K; K-Thrombyl; K-Vitan; Kaergona; Kanone; Kappaxin; Karcon; Kareon; Kativ-G; Kayklot; Kaykot; Kayquinone; Kipca-Oil Soluble; Klottone; Koaxin; Kolklot; Thyloquinone; Vitamin K 3; Vitamin K0; Vitamin K2(0); Vitamin K3; menadione; 2-Methyl-1,4-naphthalenedione; 2-Methyl-1,4-naphthochinon; 2-Methyl-1,4-naphthoquinone; 2-Methylnaphthoquinone; 2-methylnaphthalene-1,4-dione; 58-27-5; Kipca
    Click to Show/Hide
Status
Approved
Structure
Formula
C11H8O2
InChI
1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3
InChIKey
MJVAVZPDRWSRRC-UHFFFAOYSA-N
PubChem CID
4055
VARIDT Drug ID
DR01167
INTEDE Drug ID
DR1022
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Menadione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Menadione through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
Methylenetetrahydrofolate reductase (MTHFR)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Methylenetetrahydrofolate reductase (MTHFR) is a therapeutic target for Menadione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Menadione through regulating the expression of Methylenetetrahydrofolate reductase (MTHFR). [3], [4]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3279-86. doi: 10.1158/1535-7163.MCT-07-0564. Epub 2007 Dec 7.
Ref 3 A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.
Ref 4 Purification and properties of 5,10-methylenetetrahydrofolate reductase, an iron-sulfur flavoprotein from Clostridium formicoaceticum. J Biol Chem. 1984 Sep 10;259(17):10845-9.